SEC Form 4 · accession 0001193125-26-363810
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian T. Powl
Officer — Chief Commercial Officer
Period of report
Aug 21, 2026
Accepted (ET)
Aug 24, 2026 · 5:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001422143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 21, 2026 | S | 4,345 | $11.8903 | D | 169,269 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.
- F2This transaction was executed in multiple trades at prices ranging from $11.78 to $12.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.